Table 1 Baseline characteristic of included studies
Study (year) | Design | Recruit period | No. of patients (n) | Age (years) Mean (SD) | Women, No. (%) | BMI | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Tranexamic Acid | Control | Tranexamic Acid | Control | Tranexamic Acid | Control | Tranexamic Acid | Control | |||
Huang (2022) | RCT | 2017.09–2019.12 | 20 | 20 | 43.9 (11.3) | 43.9 (11.3) | 1 (5%) | 1 (5%) | N/A | N/A |
Xie (2015) | RCT | 2010.01–2012.12 | 45 | 45 | 43.4 (8.8) | 42.6 (9.8) | 3 (7.14%) | 2 (4.65%) | 24.4 (1.7) | 24.8 (1.6) |
Zhong (2021) | RCT | 2014.08–2018.04 | 34 | 19 | 43.1 (8.5) | 40.4 (8.9) | 7 (25.92%) | 4 (26.67%) | 23.8 (2.6) | 24.0 (2.5) |
Wu (2021) | RCT | 2020.04–2021.4 | 36 | 36 | 28.44 (1.78) | 28.33 (1.79) | 16 (44%) | 14 (38%) | N/A | N/A |